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Abstract
Background: Low back pain (LBP) is a common health problem and a substantial part of LBP is presumed to
be attributable to degeneration of the intervertebral disc. For patients suffering from intractable discogenic
LBP, there are few evidence-based effective interventional treatment options available. In 2010, the results of a
randomized controlled trial (RCT) were published concerning “intradiscal methylene blue injection” (IMBI), in which
this intervention appeared to be very successful in relieving discogenic pain. Therefore, we decided to repeat this
study to investigate whether we could replicate the published results. The results of our preliminary feasibility study
gave reason to set up an RCT. The aim of this RCT is to evaluate if IMBI is a more effective treatment of discogenic
low back pain as an intradiscal placebo intervention, and furthermore, to assess the cost-effectiveness of this
intervention.
Methods/Design: Consecutive discogenic low back pain patients referred to four specialized pain treatment
facilities are being screened for eligibility. After a positive standardized provocation discography and informed
consent, patients are randomized into two groups. The treatment group receives an intradiscal injection with
methylene blue, lidocaine, and contrast, and the control group receives intradiscal isotonic saline with lidocaine
and contrast.
Main outcome measures are pain at the 6-month follow-up, patient’s global impression of change, cost-
effectiveness, quality of life, disability, and analgesic intake.
Discussion: The importance of this study is emphasized by the fact that for intractable discogenic low back
pain patients, evidence-based effective pain treatments are rare. If this study establishes clinical success and
cost-effectiveness, IMBI could become the “pain treatment of choice” for a selected group of patients with
chronic discogenic low back pain for whom noninvasive treatment options have failed.
Trial registration: National Trial register NTR2547
Registered at 29 September 2010 and 31 March 2014.
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Background
Low back pain (LBP) is a common health problem; more
than 70 % of the population in industrialized countries
will experience low back pain at least once in their life
[1]. In most patients, LBP is assumed to resolve spontan-
eously, although in a recent systematic review it was
shown that 60 % of patients who went to the general
practitioner for their recent onset LBP, still suffer from
back pain one year later [2]. LBP diminishes the quality
of life of the individual patient substantially [3]. Further-
more, low back pain is also an economical problem for it
imposes a substantial financial burden on society [4–7]. A
substantial part of LBP is presumed to be attributable to
degeneration of the intervertebral disc [8–10]. In a normal
disc, nerve fibers are present only in the outer layers of
the annulus fibrosis [11]. In contrast, in a degenerated
disc, nociceptive nerves have been shown to grow into
the inner layers of the annulus fibrosis along degenera-
tive fissures [12–14]. Stimulation of these nerve endings
with inflammatory mediators is assumed to produce pain
[13, 15]. A positive provocative discography along with
morphologic signs of disc degeneration, that is, annular
tear grade II to IV according to the modified Dallas Classi-
fication, as seen during the discography procedure, is as-
sumed to confirm the diagnosis of discogenic pain [16].
The treatment of discogenic chronic low back pain re-
mains controversial. Patients who do not respond to
conservative therapy may undergo various treatments,
varying from interventional chronic pain treatment to
fusion surgery, generally with variable and unpredictable
results [17].
In 2010, results of a randomized placebo-controlled
trial concerning intradiscal methylene blue injection
(IMBI) were published [18]. It showed a clinically mean-
ingful pain reduction in 89 % of IMBI-treated patients.
The rationale for this treatment is that methylene blue
(MB) is neurolytic. Intradermal MB injection has shown
by electron microscopy to be able to destroy dermal
nerve endings [19]. By injecting methylene blue into the
nucleus pulposus, it spreads into radial fissures where it
can destroy the nerve endings or nociceptors that have
grown into the painful disc. The authors and commen-
tating author concluded that this treatment was promis-
ing but that it is imperative that more high-quality
studies are performed to determine whether the results
of this study can be reproduced.
In 2011, the Departments of Anesthesiology and Pain
Medicine of Maastricht and Arnhem in the Netherlands
started a pilot study to acquire information about effect
size, recruitment strategies, acceptability of intervention,
study burden, and safety of IMBI. The pilot indicates
that IMBI could be effective (40 % responded to the
treatment) in a well-selected group of patients suffering
discogenic pain.
The proposed placebo controlled randomized clinical
trial (RCT) was designed to investigate whether the re-
sults of the aforementioned RCT on IMBI can be repli-
cated and additionally, to assess the cost effectiveness of
this intervention.
Methods/Design
A double-blind placebo controlled randomized clinical
trial (RCT) will be conducted in four interventional pain
centers in the Netherlands by certified pain specialists.
The RCT is approved by European Union Drug Regulat-
ing Authorities Clinical Trials (EudraCT) and the medical
ethics committee (METC) of the Maastricht University
Medical Centre; registration number NL325 11.068.10
and 10-2-055, respectively. Informed consent will be ob-
tained from all participants.
This study is sponsored by ‘The Netherlands Organisa-
tion for Health Research and Development’ (ZonMw),
registration number 836011026.
Clinical trials registration number is NTR2547.
Study population
Consecutive patients with chronic lumbar axial pain re-
ferred to the specialized pain centers are assessed for eli-
gibility. Eligibility criteria are a history consistent with
lumbar discogenic pain (for example, predominant axial
pain produced on lumbar motion, significant functional
limitation in sitting duration and tolerance); low back
pain for at least 6 months, and in at least the last 6 weeks
a poor response to treatment that is, analgesics, physio-
therapy, facet blockade and radiofrequency therapy; age
between 18 and 66 years; neurological exam without
motor deficit; pain intensity of at least 5 measured with
the Numeric Rating Scale (NRS) 1 to 10 [20].
Exclusion criteria are discogenic pain confirmed on
more than two levels; extruded or sequestered herniated
nucleus pulposus; previous lumbar surgery or invasive
intradiscal procedures on suspected levels; symptomatic
lumbar spinal stenosis; grade 1-2 spondylolisthesis. Fur-
ther exclusions include BMI (Body Mass Index (kg/m2))
of ≥ 35, pregnancy, coagulopathy or oral anticoagulant
therapy (except low-dose acetylsalicylic acid) in condi-
tions that do not allow for a temporary discontinuation,
and infection. Patients who are incapable of following
verbal or written instructions or with psychiatric prob-
lems potentially interfering with cooperation in the study
will be excluded as well.
Magnetic Resonance Imaging (MRI) must have been
performed in the last 12 months before inclusion to rule
out severe disc degeneration as evidenced by a > 50 %
disc height loss at the affected level [21]. Patients
undergo a provocative discography to confirm or rule
out discogenic origin of the lumber pain [22–24]. The
provocative discography will be conducted according to
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ISIS/IASP guidelines and with the use of a pressure- and
velocity-controlled disc stimulation device (CDS) (Neu-
rotherm™, Wilmington DE, US) [23]. In provocative disc-
ography, annular tears according to the Modified Dallas
classification of annular tears scheme grade 1 to 4 (see
Table 1) in either one, or at most two, discs must be
present [13, 21]. Concordant pain provocation must be
present in the disc(s) at pressures of less than 50 PSI
above opening pressure, of at least NRS 7 (of 10) or ≥
70 % reproduction of worst spontaneous pain [25]. At
least one adjacent lumbar disc should perform as a nega-
tive control disc.
Patients who fulfil the eligibility criteria for this study
are asked to participate in the study.
Intradiscal methylene blue injection (IMBI) versus placebo
After written informed consent, patients will be random-
ized 1:1 for the treatment or control group Fig. 1. The
treatment will be performed in the daycare surgery facil-
ities of the participating specialized pain centers. To
standardize this procedure and to ensure equal quality
of treatment application, all participating physicians are
trained in performing the IMBI intervention according
to protocol.
Intradiscal methylene blue injection (IMBI) treatment
consists of intradiscal injection with 1 ml of methylene
blue, 0.5 ml of lidocaine hydrochloride 2 %, and 0.5 ml
contrast dye (Iohexol-Omnipaque 300). The placebo
treatment consists of 1 ml isotonic saline, 0.5 ml con-
trast dye, and 0.5 ml of lidocaine hydrochloride 2 %.
This solution will be injected in the affected disc(s)
under control of pressure (maximum of 100 PSI), vel-
ocity (0.02 ml/s), and volume using a CDS. During this
procedure, the patient remains blind for the study-fluid.
After the treatment, the patient has bed rest for at least
2 hours and during that time will be held in observation
at the daycare surgery unit. Data will be collected at
6 weeks and at 3, 6, 12, and 24 months after the inter-
vention, and patients will be seen by a physician or re-
search nurse at each time-point to monitor patients’
adherence to the protocol.
Allocation concealment
Both patients and post-intervention observers, such as
pain managing nurses and physicians, are to remain
blinded to the treatment or control intervention for at
least 6 months. Therefore, during the intervention the
interventional pain specialist takes care that the patient
does not see the injected fluid. By asking the patient half
an hour after the procedure what medication they think
they received - either 1) methylene blue, 2) placebo or,
3) “I really don’t know” - the efficacy of the blinding pro-
cedure shall be checked. Furthermore, the same question
will be repeated in the online patient questionnaire at 6,
12, and 24 weeks. Six-months post-intervention, at the
patient’s request, patients from the control group who
still suffer pain can receive the IMBI treatment.
Objectives
Patients are assessed at baseline, at 6 weeks, 3 months,
and at the primary end-point of 6 months, and further-
more, at the follow-up of 12, and 24 months.
Primary outcome measures is average pain at
6 months, measured by a pain diary with numeric rating
scales (NRS) three times a day for 4 consecutive days.
Success of the intervention is defined as pain reduction
of at least 30 % at 6 months.
Other study variables include the Patients Global Im-
pression of Change (PGIC) measured by a 7-point Likert
Scale and number of adverse and serious adverse events
[26]. Societal cost consisting of hospital cost and costs
outside the hospital are measured by means of cost
questionnaires. Disability is measured by the Oswestry
Disability Index [26], Quality of life (QOL) by the Rand-
36 and EQ-5D [26]. Information about pain characteris-
tics is collected using the McGill Pain Questionnaire
[26], and information about analgesics use with a diary
at each time-point for 4 days. The potential predictive
value, for success or failure of the intervention, will be
explored with use of baseline variables, MRI classifica-
tion, and registered variables of the provocative discog-
raphy [26, 27].
With the exception of the pain and medication diary,
and the health-related quality of life EuroQol (EQ-5D)
questionnaire, which are presented to the patient in a
booklet, all data will be collected by web-based ques-
tionnaires software, SelectSurvey. (NETv4.075.011©
Copyright 2008 ClassApps.com) and MACRO (version
4.1.2.3750© 1999-2012 InferMed Limited, London, UK).
Randomization and stratification
The randomization of study patients in either the treat-
ment or the control group will be done with software for
randomization of clinical trials ALEA (version 2.2
CTCM/ALEA). The stratification factors, that are used
in the randomization procedure to assure that potential
Table 1 Modified Dallas Classification [16]
Grade Grade Description
0 Contrast is within the nucleus
1 Extravasation in the inner 1/3 of the annulus
2 Extravasation in the middle 1/3 of the annulus
3 Extravasation in the outer 1/3 of the annulus
4 More than 30 degrees of annular circumference
5 Extra-annular contrast
Geurts et al. Trials  (2015) 16:532 Page 3 of 7
Fig. 1 Trial design and patient flow
Geurts et al. Trials  (2015) 16:532 Page 4 of 7
confounders are equally distributed between the two
randomized groups, are study center; gender; dichoto-
mized disc levels (1) L3/L4 to L4/L5 and (2) L5/S1; and
dichotomized Modified Dallas criteria (1) 1 to 2 and (2)
3 to 4. The software automatically sends an e-mail with
the randomization results to the un-blinded physician
who will perform the IMBI treatment.
Sample size
The sample size of the RCT is determined on the basis
of success rates in the previous RCT [18] and our pilot
[28]. We assume that 50 % of patients in the treatment
group will be successfully treated. Success is defined as
30 % pain reduction at the 6-month follow-up. In the
control group, we assume a 20 % success rate.
Given the invasive character of the IMBI procedure,
we consider that the treatment group should be at least
30 % more successful than the control group to reach
minimally clinical relevance. Furthermore, we assume
10 % drop out per group.
For a power of 80 % and a level of statistical signifi-
cance of 5 %, the minimum sample size is under these
assumptions estimated to be 80 patients, that is, 40 per
randomized group [29].
Sample size interim analysis
Given the invasive character of IMBI and the burden for
the patients, an interim analysis is pre-planned to test
whether we can stop the study preliminarily assuming
that the experimental group has a higher success rate
than the control group and to monitor planned sample
size assumptions. The sample size calculation for the in-
terim analysis is based on the assumption that a success
rate of 20 % in the placebo group is probably too high.
Therefore, we assume a success rate of 10 % at 6 months
in the placebo group, instead of 20 % success. If we de-
tect a difference in success rate of 40 % between the two
groups, the sample size is estimated to be 50 patients,
that is, 25 per randomized group with a power of 90 %
and a level of statistical significance of 2.5 % (one-sided).
Statistical analysis
Differences in success rate between the groups will be
tested with a Chi square test (univariate). Success is de-
fined as at least 30 % pain reduction at 6 months. To ac-
count for cluster effects, a linear multivariate mixed
model will be used to determine differences in pain
score changes over time. A logistic regression model will
explore possible predictors for success or failure of the
procedure. The changes after 6 months of the outcome
variables of the two groups will be compared with a
Student’s t-test.
A trial-based economic evaluation will be performed,
based on empirical data obtained in the RCT. The base-
case economic evaluation will be performed from the so-
cietal perspective, including costs inside and outside the
healthcare sector and will follow the, in 2012 published,
international guidelines [30]. The time horizon of the
economic evaluation will be 6 months. The intervention
offered in this study is primarily expected to affect mor-
bidity. So, health-related quality of life is considered as
an important outcome in these patients. Therefore, a
cost-utility analysis will be performed, with the number
of quality adjusted life years (QALYs) as the primary out-
come measure, based on the EQ-5D. Additionally, a cost-
effectiveness analysis from a healthcare perspective will be
performed in which pain reduction is used as measure of
effectiveness. So, incremental cost-effectiveness ratios will
be expressed as 1) the incremental costs per QALY (soci-
etal perspective) and the 2) incremental cost per add-
itional patient with a clinically relevant pain reduction
(healthcare perspective). The cost analysis will be per-
formed according to Dutch guidelines for cost calculations
[30]. Hospital resources use such as outpatient visits and
diagnostic procedures will be registered by Case Report
Forms. Study-related costs will not be included in the
cost-analysis. For costs outside the health care sector, such
as visits to the GP, physiotherapist, productivity losses,
and out-of pocket costs, patients will be asked to fill out
cost questionnaires with a recall period of 3 months at
three occasions: at baseline, at 3 months and at the 6-
month follow-up. Costs will be calculated by multiplying
resources use with standard unit prices [30]. Standard sen-
sitivity analyses (for example, using SF-36 for QALY calcu-
lation instead of EQ-5D) and bootstrap analysis will be
performed to investigate the uncertainty surrounding the
cost-effectiveness ratios. Based on the bootstrap results,
cost-effectiveness acceptability curves will be constructed,
showing for a wide range of cost-effectiveness threshold
values, the probability that IMBI is potential cost-effective.
The economic evaluation will only provide insight into the
potential cost-effectiveness of IMBI, as IMBI is compared
with placebo instead of a natural comparison (CAU). In a
secondary analysis, information from the baseline cost
questionnaires (covering a period of three months before
entering the study), baseline pain scores and baseline qual-
ity of life, will also be used as an estimate of costs and ef-
fects of CAU.
Monitoring
Data Monitoring Committee (DMC)
The major task of the DMC is safety monitoring. Any
serious adverse event or suspected unexpected serious
adverse reaction, which might be life threatening or li-
able to produce disability or deformity, is an indication
to set up a DMC meeting. Another important task for
the DMC is monitoring the efficacy for futility and mon-
itoring the planned sample size assumptions, whether
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criteria for early stopping are met. The statistician of the
DMC will be the only one during the trial who has ac-
cess to the un-blinded data. He performs the (interim)
analyses. Members of the DMC are (1) head of the de-
partment of orthopedic surgery and (2) statistician and
internal medical specialist of Maastricht University
Medical Centre (MUMC) the Netherlands. Each mem-
ber has no conflicts of interest with the study or the
study members. The advice(s) of the DMC will be noti-
fied upon receipt by the research committee to the
METC that approved the protocol. With this notification
a statement will be included indicating whether the ad-
vice will be followed.
This RCT will be audited and monitored by the Clin-
ical Trial Centre Maastricht (CTCM); this organization
is independent from the investigators and sponsor.
Discussion
Methylene blue (10 mg methylthioninium) is an off-label
medicine, usually used as a dye for therapeutic and diag-
nostic applications. To establish presumed efficacy and
cost-effectiveness of IMBI for discogenic LBP, a grant
was obtained from “The Netherlands Organisation for
Health Research and Development” (ZonMw).
Preceding this RCT, a pilot study with 15 discogenic
LBP patients was performed, to acquire information
about efficacy, safety, feasibility, and acceptability of this
intervention [31]. Information from this pilot study was
used for designing this randomized controlled study.
The RCT performed by Peng et al. was highly successful
(89 %). Our pilot study indicated that IMBI was success-
ful in 40 % of patients (at least 30 % pain reduction at
6 months) and this information was used to adjust the
sample size calculation. Furthermore, the pilot study
demonstrated that it was feasible to recruit a carefully
selected population of patients with discogenic LBP and
provided information about how to avoid “lost to follow-
up.” Finally, the pilot study was used to provide informa-
tion to the research funder and, consequently, enabled a
large-scale RCT.
The use of invasive placebos for pain treatment inter-
ventions is currently under debate and questions are
raised about whether it is justified to expose control
group patients to risks of serious harm [32, 33]. Since
1955, the placebo phenomenon has been considered to
have considerable clinically important effects [34]. This
view was challenged when in 2001 and 2004 systematic
reviews of clinical trials concluded that there was no evi-
dence for placebo treatments having clinically important
effects, except perhaps in patient-reported outcomes for
pain [35, 36]. The authors later published a Cochrane re-
view with similar conclusions [37]. Because in our study,
the treatment’s main objective is pain reduction as expe-
rienced by the patients, we decided to use a placebo
treatment as control. A placebo intervention, a mixture
of saline, lidocaine, and contrast will be injected to es-
tablish if there is a pain relief surplus when adding
methylene blue into the mixture instead of saline.
It is debatable if the use of the term ‘placebo’ treat-
ment is correct for lidocaine shall be injected in the con-
trol group as well as in the treatment group. Local
anesthetics are originally known for their inhibitory
function on sodium channels, but they also have import-
ant anti-inflammatory effects [38, 39]. However, the
former RCT [18], which was highly successful, also used
intradiscal lidocaine for both study arms, and they found
no large pain-relieving effect in the control group.
Providing evidence for cost-effectiveness of low back
pain interventions is a stipulated condition from the
Ministry of Health in the Netherlands. Without this evi-
dence, the Dutch Public Health Insurance System will
not reimburse low back pain interventions. Overall,
there is lack of cost-effectiveness studies for interven-
tional pain medicine; therefore, an important part of this
study concerns a cost-effectiveness assessment.
This study will generate information for health care
providers, patients, and health insurance companies, and
results can be used in future guidelines and clinical prac-
tice algorithms.
Intradiscal methylene blue injection could potentially
be a new treatment in specialized interventional pain
centers for patients with discogenic LBP who do not re-
spond favorably to conservative treatments. For these in-
tractable discogenic low back pain suffering patients,
there is currently no recommended pain treatment avail-
able; therefore, this intervention could become a “pain
treatment of last resort.”
Trial status
This is the protocol of an ongoing trial; patient recruit-
ment is not completed at the time of submission.
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